Notch homolog 1 (NOTCH1)

Overview

Notch 1 is a transmembrane receptor protein in the Notch signaling pathway, a highly conserved cell–cell communication system that regulates cell fate decisions, differentiation, proliferation, and survival. In biomedical research, NOTCH1 is especially important because dysregulated signaling can contribute to oncogenesis and abnormal tissue remodeling. Its activity is commonly studied in cancer biology, stemness, and developmental signaling contexts.

In disease settings, NOTCH1 can function as a pathway node whose activation or suppression alters transcriptional programs linked to growth and lineage commitment. Recent studies referenced here place Notch 1 in the context of T-cell acute lymphoblastic leukemia (T-ALL) and cholangiocarcinoma, and also as part of broader signaling networks involving nuclear factor kappa B, cGAS-STING/NF-κB signaling pathway, NLRP3 inflammasome, and epigenetic regulators such as P300. These contexts underscore its relevance as a mechanistic target in cancer and inflammatory biology.

Recent Publications Summary (latest 30 papers)

Recent studies have examined NOTCH1 as a disease-relevant signaling target in metabolic liver injury and T-cell acute lymphoblastic leukemia. In metabolic dysfunction-associated steatohepatitis (MASH), macrophage Notch1 activation was positively associated with hepatocyte ferroptosis in patients and mice, and macrophage-specific Notch1 knockout ameliorated liver injury, lipid accumulation, inflammation, and collagen deposition while reducing hepatocyte ferroptosis markers and improving mitochondrial structure 42437940Jul. The study further showed that exosomes from Notch1-deficient macrophages decreased hepatocyte ferroptosis, whereas tail vein infusion of exosomes from Notch1-activated macrophages aggravated ferroptosis and worsened MASH, implicating a macrophage Notch1–exosome axis in disease progression 42437940Jul.

In leukemia research, NOTCH1 was investigated in the context of T-cell acute lymphoblastic leukemia (T-ALL). A newly established T-ALL cell line, TMD11, lacked NOTCH mutations but remained sensitive to gamma-secretase inhibitors, providing a model for studying NOTCH1-related signaling and for identifying novel molecularly Targeted therapies in NOTCH-driven disease biology 42203317May. Although this report did not test a specific NOTCH1-directed intervention in patients, it supports the continued relevance of NOTCH pathway inhibition in T-ALL 42203317May.

Across these publications, NOTCH1 was studied primarily as a mechanistic signaling node rather than as a direct therapeutic agent. The MASH study linked macrophage Notch1 to exosome-mediated ferroptosis and disease worsening, while the T-ALL study highlighted a NOTCH1-unmutated leukemia model that still responded to gamma-secretase inhibition 42437940Jul42203317May.

What Changes, What Holds

1. macrophage Notch1 now appears to drive liver injury through exosome-linked ferroptosis
NEW DIRECTION The new work adds a disease mechanism not covered by the baseline: NOTCH1 is implicated in metabolic liver injury, where macrophage Notch1 activity tracks with hepatocyte ferroptosis and worsened fibrosis-related injury 42437940Jul. That extends the entity beyond cancer and developmental signaling into inflammatory-metabolic crosstalk, but it does not displace the established view of NOTCH1 as a conserved signaling receptor. The evidence is preclinical and mechanistic, so the main unresolved issue is whether this axis generalizes beyond the reported models.

2. NOTCH pathway inhibition remains relevant in T-ALL even without NOTCH mutations
REINFORCES A leukemia model that stays sensitive to gamma-secretase inhibition despite lacking NOTCH mutations strengthens, rather than revises, the baseline view that NOTCH1 signaling remains important in T-ALL 42203317May. The result supports continued use of pathway inhibition as a research and therapeutic strategy, while also showing that mutation status alone may not identify all NOTCH-dependent disease biology. It does not establish a new role for NOTCH1; it sharpens the existing one by showing that pathway dependence can persist without canonical mutations.

3. These studies broaden NOTCH1’s disease map without overturning its core signaling role
NEW DIRECTION Together, the reports extend NOTCH1 into a macrophage-driven metabolic liver injury mechanism and a mutation-negative T-ALL model that still responds to pathway blockade 42437940Jul42203317May. That broadens the baseline’s disease contexts, but it leaves intact the central account of NOTCH1 as a signaling node whose dysregulation matters in cancer and tissue remodeling. The main tension is practical rather than conceptual: the new liver data suggest a noncanonical inflammatory-metabolic axis, while the leukemia data argue that pathway inhibition can matter even when NOTCH1 is not mutated.

Overview update candidates: macrophage Notch1–exosome–ferroptosis axis in MASH; continued relevance of NOTCH pathway inhibition in T-ALL; NOTCH pathway inhibition relevance in NOTCH-unmutated T-ALL.